Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case
By Bryan Koenig · May 22, 2024, 4:58 PM EDT
Celgene and parent Bristol-Myers Squibb pointed a New Jersey federal judge to the dismissal, recently upheld by the Second Circuit, of an antitrust suit over delayed generic competition to AbbVie's hypertension...
To view the full article, register now.